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Objective: Obesity has been related to an increased risk of colorectal cancer (CRC). Adipokines
produced by the adipose tissue are directly linked to obesity and may thus contribute to the
pathogenesis of CRC. We hypothesized that potentially functional polymorphisms in the adipokine
genes leptin (LEP), leptin receptor (LEPR), resistin (RETN), and adiponectin (ADIPOQ) may be
associated with CRC.
Design and methods: We studied the association of four putatively functional single nucleotide
polymorphisms (SNPs) with CRC risk using a hospital-based study design with 702 cases and 752
controls from the Czech Republic. We used likelihood ratio tests to select the best model to represent the
relationship between genotypes and risk of CRC. Age-adjusted odds ratios (ORs) under the best model
were calculated for each SNP. Previous genotyping data on insulin (INS)-related genes were used to
explore interactions between genes in obesity- and diabetes-related pathways by using two
independent methods, logistic regression, and multifactor-dimensionality reduction.
Results: A trend to associate between the RETN SNP rs1862513 (C-420G) and CRC risk was observed
(per allele OR 1.18, 95% confidence interval (0.99–1.40). Statistically, significant interactions were
observed between the INS SNP rs3842754 (C1127INSPstI) genotypes and both the LEPR SNP
rs1137101 (Q223R) and the ADIPOQ SNP rs266729 (C-11374G) genotypes.
Conclusions: Our results suggest that variants in the adipokine genes may affect CRC risk in
combination with variants in diabetes-related genes.
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Obesity has been consistently associated with increased
risk of cancer, including the risk of colorectal cancer
(CRC) (1, 2). Both family-based and twin studies have
indicated a strong heritable component for individual
body mass index (BMI) (3, 4). The 2005 update of the
human obesity gene map contains 253 quantitative-
trait loci, and 22 gene associations, which have been
replicated in at least five studies (5). Among these 22
genes are four adipokine genes, adiponectin (ADIPOQ),
leptin (LEP), leptin receptor (LEPR), and resistin
(RETN), which are expressed in and whose products
are secreted by the adipose tissue. Adipokines can
exert their biological actions on target cells by endocrine
as well as by paracrine mechanisms. In addition to
obesity, adipokines have been associated with severalndocrinologyobesity-related disorders, such as type 2 diabetes,
cardiovascular disease, inflammation, and CRC (6–9).
Plasma leptin levels are elevated in obesity and they
increase with increasing fat mass (8). Leptin can also
act as a mitogen, transforming factor or migration
factor for many different cell types, including normal
and neoplastic colon epithelial cells (8, 10, 11). Several
prospective case–control studies have associated
increased leptin levels with increased CRC risk
(12–15). Leptin exerts its physiological action through
the leptin receptor, which is expressed in colon cancer
cell lines as well as in human normal colonic tissue and
adenomatous polyps (10, 11). Resistin levels are also
increased in both genetic and diet-induced obesity in
mice (16). Recently, increased resistin protein
expression has been observed in CRC tissue compared
with the paired normal tissue (17). In contrast to highDOI: 10.1530/EJE-09-0039
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been shown to associate with obesity and to confer a
substantially increased risk for diabetes, cardiovascular
diseases and several cancers, including CRC (6, 7, 18,
19), although in one study, no association with CRC was
observed (20). However, a recent study suggests that the
leptin/adiponectin ratio may be a better marker for
factors of metabolic syndrome than any of the
individual adipokines (14).
In humans, several single nucleotide polymorphisms
(SNPs) have been identified in the LEP, LEPR, RETN,
and ADIPOQ genes. The G-2548A polymorphism
(rs7799039) in the LEP gene has been shown to affect
leptin secretion in vitro and the strength of a complex
formation with a nuclear protein (21). Studies about the
effects of the SNP on leptin levels and obesity have been
contradictory (21–26). The glutamine to arginine
substitution (Q223R, rs1137101) in the LEPR gene
lies within the first cytokine domain in the region
encoding the extracellular domain of the leptin receptor
and it has been shown to affect serum leptin-binding
activity (27). In relation to the measures of body weight
and insulin sensitivity, the Q223R polymorphism has
been reported to explain 5% of the variance in percent
fat mass and BMI (28) as well as insulin sensitivity (29).
However, recent meta-analyses have not found any
evidence for association of the Q223R polymorphism
with the measures of obesity (30, 31).
The C-420G (rs1862513) SNP, in the promoter
region of the RETN gene, has been associated with
basal promoter activity in adipocytes and resistin
mRNA levels in human abdominal s.c. fat (32). Several
studies have found associations between the SNP and
obesity, insulin sensitivity and insulin resistance
(32–34). A high heritability has been observed for
plasma adiponectin levels in French Caucasian families
(35). Several investigators have characterized SNPs in
the ADIPOQ gene and found one or more of these SNPs
to be associated with adiponectin levels and obesity as
well as with diabetes (35–38).
Here, we investigated the effect of SNPs in the
adipokines on the CRC risk. We selected SNPs in the
LEP, LEPR, RETN, and ADIPOQ genes based on their
suggested effect on the gene expression or the protein
function as described above. We investigated their
association with the CRC risk in a Czech nationwide,
hospital-based case–control population with 702 cases
with histologically confirmed CRC and 752 controls
with negative colonoscopic results for malignancy or
idiopathic bowel diseases. Previously, we have studied
the effect of SNPs in the INS, INSR, IGFB1, IRS1, and
IRS2 on CRC risk in the same population (39). As both
insulin pathway and adipokines are associated with
diabetes and obesity and adipokines directly affect
insulin secretion (1), we additionally evaluated the
effect of gene–gene interactions in these two groups of
genes on the risk of CRC.www.eje-online.orgMaterials and methods
Subjects
The present hospital-based case–control study is based
on incident cases recruited between September 2004
and February 2006. Cases were CRC patients visiting
one of the nine oncological departments distributed in
all geographic regions of the Czech Republic (two in
Prague, one each in Benesov, Brno, Liberec, Ples,
Pribram, Ústı́ nad Labem, and Zlı́n), thus representing
the population of the entire country. During the study
period, a total of 968 cases were diagnosed with CRC in
these hospitals. Sixteen individuals were initially
excluded, because they met the Amsterdam criteria I
and II for hereditary CRC. This study includes 702
(72.5%) patients, who provided biological samples of
sufficient quality for genetic analysis. The lost cases
were similar to those enrolled with respect to age and
sex. All cases had positive colonoscopic results for
malignancy, histologically confirmed as colon or rectal
carcinomas.
Controls were recruited in the same period as the
cases. They were subjects undergoing colonoscopy for
various gastrointestinal complaints and in the frame of
preventive examination in five large gastroenterological
departments (Prague, Brno, Jihlava, Liberec, and
Pribram). The distribution of controls from different
parts of the Czech Republic was approximately the same
as that of cases. The reasons for colonoscopic investi-
gation were i) macroscopic bleeding, ii) positive fecal
occult blood test (FOBT), and iii) abdominal pain
of unknown origin. Owing to the high incidence of
CRC in the Czech Republic, colonoscopy is largely
recommended and practiced, and it is compulsory in
case of positive FOBT. The most common findings for
these subjects were hemorrhoids or idiopatic bowel
diseases (IBD). Only subjects whose colonoscopic results
were negative for malignancy, colorectal adenomas,
benign polyps or IBD were chosen as controls. From 899
selected controls, 752 (83.6%) accepted to participate,
gave a blood sample and were analyzed in this study; the
lost controls were similar to those included to the study
with respect to age and sex. DNA was isolated from
peripheral leucocytes within 4 weeks after the blood
sample was collected using the standard proteinase K
digestion, phenol/chloroform extraction and ethanol
precipitation, and stored at K80 8C.
Study subjects provided information on their lifestyle
habits (smoking, drinking, diet), BMI, diabetes and
family/personal history of cancer, using structured
questionnaires. Table 1 shows several characteristics
of the study population at the time of recruitment. The
median age of the cases was 62 (range 27–85) and of
the controls 54 (range 29–91). Information on BMI at
the time of diagnosis of cases and at the time of sample
collection of the controls and on treatment for diabetes
was available for 65.5% of cases and 66.9% of controls.
Table 1 Selected characteristics of the study population.
Cases Controls P value
Total study population (n) 702 752
Gender (n (%)) 0.59
Males 400 (57.0) 439 (58.4)
Females 302 (43.0) 313 (41.6)
Median age (years (range)) 62 (27–85) 54 (29–91) !0.0001
Missing data (n (%)) 26 (3.7) 1 (0.1)
Median BMI (kg/m2 (range)) 26.5 (13.1–44.9) 26.4 (16.6–44.3) 0.79
Missing data (n (%)) 242 (34.5) 249 (33.1)
Self-reported diabetes (n (%)) 73 (15.9) 52 (10.3) 0.01
Missing data 242 (34.5) 249 (33.1)
Smoking status (n (%)) 0.97
Non-smoker 343 (53.3) 220 (53.1)
Ex-smoker O5 years 151 (23.3) 91 (22.0)
Ex-smoker %5 years 59 (9.2) 18 (4.3)
Current smoker 91 (14.1) 85 (20.5)
Missing data 58 (8.3) 338 (44.9)
Alcohol intake (n (%)) 0.05
No 223 (47.3) 168 (41.1)
Yes 248 (52.7) 244 (59.2)
Missing data 231 (32.9) 340 (45.2)
Diet (n (%)) 0.16
Vegetarian 50 (10.7) 29 (7.8)
Non-vegetarian 418 (89.3) 342 (92.2)
Missing data 234 (33.3) 381 (50.7)
Place of residence (n (%)) 0.06
Town 266 (56.8) 231 (56.1)
TownCcountry 73 (15.6) 87 (21.1)
Country 129 (27.6) 94 (22.8)
Missing data 234 (33.3) 340 (45.2)
Education (n (%)) 0.02
Basic school 158 (33.8) 105 (25.5)
High school 239 (51.2) 225 (54.7)
University 70 (15.0) 81 (19.7)
Missing data 235 (33.5) 341 (45.3)
BMI, body mass index; n, number of individuals.
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w67% of cases and w54% of controls. All participants
gave informed written consent and the design of the
study was approved by the Ethical Committee of the
Institute of Experimental Medicine, Prague, Czech
Republic.Genotyping using TaqMan assay
The polymorphisms G-2548A (rs7799039) in the LEP
gene, Q223R (rs1137101) in the LEPR gene, C-420G
(rs1862513) in the RETN gene and C-11374G
(rs266729) in the ADIPOQ gene were investigated
using the allelic discrimination method. TaqMan
primers and probes were ordered as Assay-on-Demand
(Assay ID: C__1328079_10, C__8722581_10,
C__1394112_10, and C__2412786_10 for the LEP,
LEPR, RETN, and ACDC genes respectively) from Applied
Biosystems (Foster City, CA, USA). The reaction was
performed in 5 ml using 225 nM each primer, 50 nM
each probe and 2.5 ml TaqMan Universal 2! PCR
Master Mix (Applied Biosystems) per reaction. PCR was
performed at 50 8C for 2 min, 95 8C for 10 min followed
by 40–55 cycles at 92 8C for 15 s and 60 8C for 1 min.PCR was performed in a GeneAmp PCR System 9700
thermocycler and the number of cycles was dependent
on the genotype clustering. The samples were read and
analyzed on the ABI Prism 7900HT sequence detection
system using SDS 1.2 software (Applied Biosystems).DNA sequencing
About 10% of the genotyped samples were sequenced in
order to verify the results obtained by TaqMan. All
sequencing results were concordant with the original
results. PCR amplification and sequencing reaction
were performed as described previously (39).Statistical analysis
The observed genotype frequencies in controls were
tested for Hardy-Weinberg equilibrium (HWE). The best
model to represent the relationship between the
genotypes and the risk of CRC was selected based on
likelihood ratio tests. Odds ratios (ORs) with 95%
confidence intervals (CIs) were estimated by logistic
regression. Statistical significance for a different geno-
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considered statistically significant when the 95% CIs did
not include unity. With the present sample size, our
study had a power of 78% to detect a per allele OR of 1.3
for a SNP with a minor allele frequency (MAF) of 26%
(the lowest MAF in the studied SNPs). The optimal
combination of SNPs to describe the relationship
between genotypes and risk of CRC was selected using
Akaike’s information criterion (AIC) (40). In our
calculations, the lower the AIC value, the better the
model. To identify possible high-order gene–gene
interactions among the adipokine genes, multifactor-
dimensionality reduction (MDR) followed by permu-
tation analyses was applied (41). This method has been
developed to detect and characterize combinations of
multi-locus genotypes that are associated with a specific
disease. Shortly, MDR classifies multi-locus genotypes
into high-risk and low-risk groups. The advantages of
the method are that no mode of inheritance has to be
assumed, and false-positive results due to multiple





















































































































































































































































































































































































































































































































































































































































































































































































































































































































The genotype distributions of the four studied SNPs
were according to HWE in the control population. The
allele and the genotype distributions shown in Table 2
were concordant with the previously published studies
for Caucasians (25, 31–33, 35, 36, 42) or for the CEPH
(Utah residents with ancestry from northern and
western Europe) population in the International
HapMap Project (http://www.hapmap.org/index.html.en).
Data on BMI and diabetes was available from 65.5%
of CRC cases and 66.9% of controls (Table 1). Among
them, the median BMI was practically identical in the
cases (26.4) and the controls (26.5; PZ0.79), and the
BMI did not depend on the genotypes (data not shown).
Self-reported diabetes was more common among the
CRC patients than the controls (PZ0.01), but the
investigated SNPs did not seem to modify susceptibility
to diabetes. Among the lifestyle factors, the cases
seemed to have slightly lower education level than the
controls (PZ0.02), but this result may be influenced by
the different percentage of missing data in cases (33.5%)
compared with controls (45.3%). Age-adjusted ORs
under the best model, selected by likelihood ratio tests,
were calculated for each SNP. As shown in Table 2, only
the RETN genotypes showed a trend to association with
CRC with a global p-value of 0.06 and the per minor
allele G OR of 1.18 (95% CI 0.99–1.40). After additional
adjustment for diabetes and education level, this
association lost its statistical significance (OR 1.08,
95% CI 0.87–1.34).
We used logistic regression and MDR to evaluate
interactions between the cytokine genes genotyped in
this study and the insulin-related genes genotyped
in our previous study (39). Based on the case–controlwww.eje-online.org
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statistically significant interactions were observed
between the SNPs in the LEPR and the INS genes (P
value for multiplicative interaction 0.02) and between
the ADIPOQ and the INS genes (P value 0.03;
Supplementary Table 1, which can be viewed online
at http://www.eje-online.org/supplemental/). The MDR
analysis confirmed this finding and indicated that the
best model to describe the case/control distribution was
based on variants of the LEPR and the INS genes
(Fig. 1). Permutation analyses revealed the statistical
significance of this classification (PZ0.02). Subsequent
likelihood ratio tests and AIC values suggested a model
with three variants for the LEPR gene and dominant
effects for the INS gene (Supplementary Table 2, which
can be viewed online at http://www.eje-online.org/
supplemental/). The association analysis indicated an
increased CRC risk for carriers of the GG genotype of the
LEPR gene and at least one variant allele of the INS gene
compared with the carriers of the wild-type genotypes of
these two SNPs (age-adjusted OR 1.64, 95% CI 1.02–
2.65; Fig. 1), the association was slightly stronger after
additional adjustment for diabetes and education level
(OR 2.04, 95% CI 1.08–3.85). The MDR analysis
confirmed this result and pointed to a complex
interaction between the LEPR and the INS variants
(Fig. 1, upper panel). The interaction between variants
in the ADIPOQ and the INS genes was also complex
(Fig. 1, lower panel). Compared with the wild-typeFigure 1 Interactions of LEPR and INS as well as of ADIPOQ and IN
dimensionality reduction. The high risk genotype combinations (i.e., c
boxes and the low risk combinations (with more controls than cases)
cases and right bars the number of controls. On the right, distribution
and the ADIPOQ (rs266729)-INS (rs3842754) genotype combinations
(CIs). The ORs were considered statistically significant, when the 95%genotype carriers, carriers of the variant allele of the
ADIPOQ gene showed a decreased risk of CRC, when the
INS genotype was CC (age-adjusted OR 0.73, 95% CI
0.55–0.98), and when the INS genotype was TT (age-
adjusted 0.37, 95% CI 0.16–0.84). However, the last
association should be taken with caution, because of
low numbers of cases (nZ9) and controls (nZ22)
carrying the genotype combination. These associations
did not remain statistically significant after additional
adjustment for diabetes and education level (Fig. 1).Discussion
Adipokines, secreted by the adipose tissue, are strong
candidates for the link between obesity and risk of CRC
(1, 6). In order to investigate the influence of potentially
functional genetic variation in the adipokine genes LEP,
LEPR, RETN, and ADIPOQ on the CRC risk, we
genotyped SNPs in these genes in a cohort of cases
and controls from the Czech Republic. As adipokines
regulate the function of insulin pathway and we have
previously studied the effect of insulin-related genes on
CRC in the same population (39), gene–gene
interactions between genes in the two pathways were
also investigated.
It is well known that the curse of dimensionality
diminishes the usefulness of traditional, parametric
methods and that no single approach is optimal for allS genotypes. On the left, the interactions according to multifactor-
ombinations with more cases than controls) are shown in dark grey
in light grey boxes. In each box, left bars represent the number of
of the LEPR (rs1137101)-INS (rs3842754) genotype combinations
with age-adjusted odds ratios (ORs) and 95% confidence intervals
CIs did not overlap unity, as indicated by bold.
www.eje-online.org
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regression, the standard method for analysis of data
from case–control studies, only interaction terms of
variables with significant main effects are tested for
significance (45, 46). Therefore, logistic regression lacks
by definition the ability to characterize purely interactive
effects. In complex diseases, such as CRC, a majority of
genes may be difficult to identify due to their modest
individual effects and complex interactions (47). Multi-
dimensionality reduction was developed to detect gene–
gene interactions in the presence or absence of main
effects in case–control studies and we decided to apply
also this method to analyze our data. The present
logistic regression data suggested that SNPs in the LEPR
and the ADIPOQ genes interact with the SNP in the INS
gene at a statistically significant level, but the two genes
did not show independent main effects. The possible
interaction between LEPR and INS was shown by
MDR analysis, which also selected this combination
of genes to describe the distribution of cases and
controls. Likelihood ratio tests and the values of the
AIC indicated that the best model to represent CRC risk
consisted of three genotypes for the LEPR SNP and a
dominant penetrance model for the INS SNP. For the
possible interaction between the ADIPOQ and the INS
genes the best model consisted of a dominant model
for the ADIPOQ SNP and a three genotype model for
the INS gene.
The reported functional effects of the studied SNPs
support our observations about a link between the SNPs
in adiposity-related adipokines, in the insulin pathway
and risk of CRC. The LEPR SNP Q223R has been shown
to affect serum leptin-binding affinity, with individuals
homozygous for the R allele having higher serum leptin-
binding affinity than carriers of the Q allele (27).
Homozygosity for the R allele has also been associated
with obesity and it has been reported to explain some
5% of the variance in percent fat mass and BMI (28). In
another study, the R allele was associated with insulin
sensitivity explaining about 6–7% of the variance in the
trait (29). Since many studies, including two meta-
analyses (30, 31), have failed to show an association
with obesity phenotypes and the positive associations
are mainly observed in young and/or healthy popu-
lations, Chiu et al. speculated that this SNP may
contribute to the initiation events leading to insulin
resistance (29). A part of the inter-individual variation
in adiponectin levels may be explained by the ADIPOQ
promoter SNPs, including the C-11374G SNP (35).
Although the low-level -11374G allele has been
associated with obesity, its association with diabetes
seems to depend on the level of obesity (35, 36, 38). The
common partner of the gene–gene interactions
observed in our study, the INS SNP C1127INSPst1
(rs3842752) may regulate insulin production due to its
location in the regulatory 3 0-UTR (48) or due to its
linkage disequilibrium with a variable number-tandemwww.eje-online.orgrepeat (VNTR) locus in the promoter of the gene, which
has consistently been associated with diabetes (49).
In the single SNP analysis, only the RETN SNP
C-420G showed a trend to association with CRC risk
based on an additive model (per allele OR 1.18; 95% CI
0.99–1.40). In the recent study by Wågsäter et al. no
statistically significant difference in the genotype
distribution between the cases (nZ248) and the
controls (nZ256) was observed, although the GG
genotype was more common among the cases
(10.5%) than the controls (6.3%) (17). The effect of
the G allele is biologically plausible, because the G allele
has been associated with both increased basal promoter
activity and higher resistin mRNA levels in human
abdominal s.c. fat as well as in insulin resistance and
obesity (32, 33). An alternative mechanism linking
RETN with CRC is through inflammation, a known risk
factor for CRC (50), because in humans resistin has
been shown to be produced mainly in the macrophages
within the adipose tissue (9).
In addition to the report about the relationship
between the RETN SNP C-420G and the risk of CRC
(17), only one study has addressed the question of an
association between genetic variation in the adipokine
genes and the risk of CRC (51). In that study, a decreased
risk for the AA genotype carriers of the SNP rs2167270
in the 5 0-UTR of the LEP gene was observed.
Additionally, a decreased OR was observed for a
combination of the LEP SNP rs21672709 and the
SNP rs6588147, located in intron 2 of the LEPR gene.
Slattery et al. (51) observed an interaction between the
LEP and the LEPR SNPs and polymorphisms in the
insulin-like growth factor-1 and the IRS2 genes.
According to HapMap (http://www.hapmap.org/index.
html.en) the SNP rs2167270 in the LEP gene is in a
partial linkage disequilibrium with the SNP rs7799039
(D 0Z1.0, r2Z0.47) analyzed in our study, and the SNP
rs6588147 in the LEPR gene shows low linkage
disequilibrium with the SNP rs1137101 (D 0Z0.70,
r2Z0.34) genotyped by us. Thus, although the SNPs
studied by Slattery et al. (51) and by us are different
and do not show high linkage disequilibrium with
each other, both studies suggest an interaction of
the adipokine and the INS-related genes in the etiology
of CRC.
The strengths of our study include the relatively large
sample size, 702 cases and 752 controls, and the
selection of SNPs based on previous functional data.
Additionally, we were able to study gene–gene
interactions between genes in two obesity- and
diabetes-related pathways, because the genotyping
data on insulin-related genes in the same population
were available from our previous study. The limitations
of our study include the difference in age between the
cases and the controls. However, no age or gender
specific differences in the genotype distributions were
observed. Another limitation was the presence of
missing data on BMI, diabetes, and lifestyle habits,
Polymorphisms in adipokine genes and CRC 939EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009) 160which may be related to work overload in some of the
participating departments. Especially, for lifestyle habits,
the answering rate was much lower among the controls
(about 55%) than among the cases (about 67%). BMI
data were recorded in the cases at the time of diagnosis
and diabetes was self-reported, thus probably restricting
the adequacy of this information. When individuals
without information on age, genotype, diabetes or
education were excluded from the analyses, the
reduction in sample size resulted in non-significant
associations. It should be kept in mind that different
patterns of missing data in cases and controls may have
resulted in spurious associations. Regarding the statisti-
cal methods used, it has been reported that standard
methods for gene–gene interaction studies are not
feasible and the results may be difficult to interpret
(41). In our study, this was especially clear for the
interaction between the ADIPOQ and the INS genes,
where both wild-type and variant homozygous geno-
types of the INS gene together with at least one variant
allele of the ADIPOQ gene associated with decreased risk
of CRC.
In conclusion, our results suggest that SNPs in the
adipokine genes may affect the risk of CRC together
with SNPs in other genes related to obesity or diabetes.
This observation is relevant from both a practical
and a scientific point of view and it warrants further
studies using both large, independent cohorts, and a
population-based approach.Declaration of interest
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